ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Development of a machine learning-based radiomics signature for estimating breast cancer TME phenotypes and predicting anti-PD-1/PD-L1 immunotherapy response

Han, Xiaorui; Guo, Yuan; Ye, Huifen; Chen, Zhihong; Hu, Qingru; Wei, Xinhua*; Liu, Zaiyi*; Liang, Changhong*广东省人民医院; 广州大学; 南方医科大学; 1
BREAST CANCER RESEARCH2024-1-29DOI: 10.1186/s13058-024-01776-y
4阅读
引用收藏
分享

摘要

Backgrounds Since breast cancer patients respond diversely to immunotherapy, there is an urgent need to explore novel biomarkers to precisely predict clinical responses and enhance therapeutic efficacy. The purpose of our present research was to construct and independently validate a biomarker of tumor microenvironment (TME) phenotypes via a machine learning-based radiomics way. The interrelationship between the biomarker, TME phenotypes and recipients' clinical response was also revealed. Methods In this retrospective multi-cohort investigation, five separate cohorts of breast cancer patients were recruited to measure breast cancer TME phenotypes via a radiomics signature, which was constructed and validated by integrating RNA-seq data with DCE-MRI images for predicting immunotherapy response. Initially, we constructed TME phenotypes using RNA-seq of 1089 breast cancer patients in the TCGA database. Then, parallel DCE-MRI images and RNA-seq of 94 breast cancer patients obtained from TCIA were applied to develop a radiomics-based TME phenotypes signature using random forest in machine learning. The repeatability of the radiomics signature was then validated in an internal validation set. Two additional independent external validation sets were analyzed to reassess this signature. The Immune phenotype cohort (n = 158) was divided based on CD8 cell infiltration into immune-inflamed and immune-desert phenotypes; these data were utilized to examine the relationship between the immune phenotypes and this signature. Finally, we utilized an Immunotherapy-treated cohort with 77 cases who received anti-PD-1/PD-L1 treatment to evaluate the predictive efficiency of this signature in terms of clinical outcomes. Results The TME phenotypes of breast cancer were separated into two heterogeneous clusters: Cluster A, an "immune-inflamed" cluster, containing substantial innate and adaptive immune cell infiltration, and Cluster B, an "immune-desert" cluster, with modest TME cell infiltration. We constructed a radiomics signature for the TME phenotypes ([AUC] = 0.855; 95% CI 0.777-0.932; p < 0.05) and verified it in an internal validation set (0.844; 0.606-1; p < 0.05). In the known immune phenotypes cohort, the signature can identify either immune-inflamed or immune-desert tumor (0.814; 0.717-0.911; p < 0.05). In the Immunotherapy-treated cohort, patients with objective response had higher baseline radiomics scores than those with stable or progressing disease (p < 0.05); moreover, the radiomics signature achieved an AUC of 0.784 (0.643-0.926; p < 0.05) for predicting immunotherapy response. Conclusions Our imaging biomarker, a practicable radiomics signature, is beneficial for predicting the TME phenotypes and clinical response in anti-PD-1/PD-L1-treated breast cancer patients. It is particularly effective in identifying the "immune-desert" phenotype and may aid in its transformation into an "immune-inflamed" phenotype.

学科与关键词

关键词
Machine learningRadiomics signatureBreast cancerTumor microenvironment
相关
加载中…
  • Radiomics Assessment of the Tumor Immune Microenvironment to Predict Outcomes in Breast Cancer
    Han, Xiaorui; Cao, Wuteng; Wu, Lei; Liang, Changhong*Frontiers in Immunology, 2022, 12: 773581.被引 10
  • Magnetic resonance imaging radiomics predicts preoperative axillary lymph node metastasis to support surgical decisions and is associated with tumor microenvironment in invasive breast cancer: A machine learning, multicenter study
    Yu, Yunfang; He, Zifan; Ouyang, Jie; Tan, Yujie; Chen, Yongjian; Gu, Yang; Mao, Luhui; Ren, Wei; Wang, Jue; Lin, Lili; Wu, Zhuo; Liu, Jingwen; Ou, Qiyun; Hu, Qiugen; Li, Anlin; Chen, Kai; Li, Chenchen; Lu, Nian; Li, Xiaohong; Su, Fengxi; Liu, Qiang; Xie, Chuanmiao*; Yao, Herui*EBioMedicine, 2021, 69: 103460.被引 84
  • Performance of radiomics models for tumour-infiltrating lymphocyte (TIL) prediction in breast cancer: the role of the dynamic contrast-enhanced (DCE) MRI phase
    Tang, Wen-jie; Kong, Qing-cong; Cheng, Zi-xuan; Liang, Yun-shi; Jin, Zhe; Chen, Lei-xin; Hu, Wen-ke; Liang, Ying-ying; Wei, Xin-hua; Guo, Yuan*; Jiang, Xin-qing*European Radiology, 2022, 32(2): 864-875.被引 17
查看全部 →

发表信息

论文状态
公开发表
期刊
BREAST CANCER RESEARCH
发表日期
2024-01-29
卷期
第 26 卷, 第 1 期
页码
18
DOI
10.1186/s13058-024-01776-y
语言
ENGLISH
成果收录
SCIE
资助标注
Key-Area Research and Development Program of Guangdong Province

作者

  • H

    Han, Xiaorui (第一作者)

    1 · guangdong prov peoples hosp · southern med univ

  • G

    Guo, Yuan

    1

查看全部 8 位作者收起作者
  • Y

    Ye, Huifen

    2 · southern med univ · guangdong prov peoples hosp

  • C

    Chen, Zhihong

    guangzhou univ

  • H

    Hu, Qingru

    guangdong prov peoples hosp · southern med univ · 2

  • W

    Wei, Xinhua (通讯)

    1

  • L

    Liu, Zaiyi (通讯)

    guangdong prov peoples hosp · southern med univ

  • L

    Liang, Changhong (通讯)

    guangdong prov peoples hosp · southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417